Antibody Recruiting Molecule BHV-1100 with Autologous Memory-like Natural Killer Cell Therapy Plus Intravenous Immunoglobulin, Followed by Low-Dose IL-2 in Multiple Myeloma Patients in the Peri-autologous Stem Cell Transplant Setting

Enrollment open to Dana-Farber Cancer Institute patients. For questions and enrollment in the Phase 1 study, please call the number below and reference the trial ID NCT04634435.

+ 1 877-DF-TRIAL
(+ 1 877-338-7425)

For more information on the study, please visit clinicaltrials.gov.